摘要
目的观察唑来膦酸注射液治疗转移性骨肿瘤的疗效及安全性。方法44例恶性肿瘤骨转移患者采用唑来膦酸(天晴依泰)注射液4mg加入0.9%氯化钠注射液100ml静脉滴注15分钟以上;同时以35例恶性肿瘤骨转移患者使用帕米膦酸二钠(博宁)注射液60mg加入0.9%氯化钠注射液500ml静脉滴注4小时以上作为对照。两组均一次性给药后观察14天。结果治疗骨痛有效率唑来膦酸组为81.08%,帕米膦酸二钠组为69.70%,两组疗效差异有显著性(P<0.05)。活动能力有效率唑来膦酸组为40.91%,帕米膦酸二钠组为45.71%,两组疗效差异无显著性(P>0.05)。不良反应发生率唑来膦酸组为45.45%,帕米膦酸二钠组为42.86%,差异无显著性(P>0.05),均主要表现为发热、低钙血症、肌肉酸痛,予对症处理后症状消失。结论唑来膦酸是一种有效的第三代双膦酸盐制剂,可方便安全地用于恶性肿瘤骨转移的治疗。
Objective To evaluate the safety and efficacy of zoledronic acid in the treatment of skeletal metastases in patients with malignant tumors. Methods 79 patients with metastatic bone cancer were randomized divided into two groups： 44 patients received intravenous infusion of zoledronic acid （4mg, treatment group） for 15 minutes; and 55 patients received pamidronate （90rag, control group） for 4 hours. The efficacy was observed in 14 days post drug therapy. Results Patients in treatment group showed an overall response rate of 81.08%, compared with 69.70% in control group （P 〈 0.05 ）. No significant differences were found in the improvement in quality of life （40. 91% versus 45.71%, respectively ）, and in the incidence rate of adverse reactions （45.45% versus 42. 86%, respectively）, such as fever, hypocalcemia, muscular soreness. Conclusion Zoledronic acid can be used in the treatment of skeletal metastases safely and conveniently.
出处
《癌症进展》
2006年第6期554-557,共4页
Oncology Progress
